Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation

<p>SNP ID.</p>

保存先:

書誌詳細
第一著者:	Francesca Orzan (15055579) (author)
その他の著者:	Francesca De Bacco (15055582) (author), Elisabetta Lazzarini (15055585) (author), Giovanni Crisafulli (15055588) (author), Alessandra Gasparini (15019568) (author), Angelo Dipasquale (15055591) (author), Ludovic Barault (15030747) (author), Marco Macagno (15030744) (author), Pasquale Persico (15055594) (author), Federico Pessina (15055597) (author), Beatrice Bono (15055600) (author), Laura Giordano (15055603) (author), Pietro Zeppa (15055606) (author), Antonio Melcarne (15055609) (author), Paola Cassoni (15055612) (author), Diego Garbossa (15055615) (author), Armando Santoro (15034235) (author), Paolo M. Comoglio (15055618) (author), Stefano Indraccolo (15027102) (author), Matteo Simonelli (15055621) (author), Carla Boccaccio (15055624) (author)
出版事項:	2025
主題:	Cancer Therapeutic Research and Development Methods and Technology CNS Cancers Gliomas, Glioblastomas Liquid Biopsy Translational Research
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
著者:: Francesca Orzan (15055579)
出版事項: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
著者:: Francesca Orzan (15055579)
出版事項: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
著者:: Michael Kilian (16697663)
出版事項: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
著者:: Michael Kilian (16697663)
出版事項: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
著者:: Michael Kilian (16697663)
出版事項: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
著者:: Mengjie Zhao (14845174)
出版事項: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
著者:: Min Wu (14962986)
出版事項: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
著者:: Min Wu (14962986)
出版事項: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
著者:: Min Wu (14962986)
出版事項: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
著者:: Min Wu (14962986)
出版事項: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
著者:: William Kelly (15439117)
出版事項: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
著者:: William Kelly (15439117)
出版事項: (2025)

Data Sheet 3_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
著者:: Hailong Pang (12841991)
出版事項: (2025)

Data Sheet 2_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
著者:: Hailong Pang (12841991)
出版事項: (2025)

Data Sheet 1_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
著者:: Hailong Pang (12841991)
出版事項: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
著者:: N. Ari Wijetunga (15056183)
出版事項: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
著者:: N. Ari Wijetunga (15056183)
出版事項: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
著者:: N. Ari Wijetunga (15056183)
出版事項: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
著者:: N. Ari Wijetunga (15056183)
出版事項: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
著者:: Sied Kebir (15048732)
出版事項: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
著者:: Defne Bayik (14961098)
出版事項: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
著者:: Qingsheng Xu (17078830)
出版事項: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
著者:: Qingsheng Xu (17078830)
出版事項: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3juulf7gd9auvflh0crri81n0f